ImmunityBio Faces FDA Warning Over Bladder Cancer Drug Promotion

ImmunityBio's shares experienced a significant decline following a warning letter from the U.S. Food and Drug Administration (FDA) regarding the promotion of its bladder cancer drug, Anktiva. Bloomberg posted on X, highlighting that the FDA accused the biotechnology company and its billionaire Executive Chairman, Patrick Soon-Shiong, of false and misleading promotion practices. The FDA's letter emphasized concerns over the promotional materials related to Anktiva, which it deemed to be misleading. This development has raised questions about the company's marketing strategies and compliance with regulatory standards. The impact of the FDA's warning was immediately felt in the stock market, as ImmunityBio's shares dropped sharply. Investors are now closely monitoring the situation to assess the potential implications for the company's future operations and financial performance.